GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (OTCPK:RVLPQ) » Definitions » 5-Year ROIIC %

RVL Pharmaceuticals (RVL Pharmaceuticals) 5-Year ROIIC % : 7.54% (As of Dec. 2022)


View and export this data going back to 2018. Start your Free Trial

What is RVL Pharmaceuticals 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. RVL Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Dec. 2022 was 7.54%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for RVL Pharmaceuticals's 5-Year ROIIC % or its related term are showing as below:

RVLPQ's 5-Year ROIIC % is ranked better than
66.57% of 1376 companies
in the Biotechnology industry
Industry Median: -19.255 vs RVLPQ: 7.54

RVL Pharmaceuticals 5-Year ROIIC % Historical Data

The historical data trend for RVL Pharmaceuticals's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RVL Pharmaceuticals 5-Year ROIIC % Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
5-Year ROIIC %
Get a 7-Day Free Trial - - - 9.73 7.54

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 7.54 - -

Competitive Comparison of RVL Pharmaceuticals's 5-Year ROIIC %

For the Biotechnology subindustry, RVL Pharmaceuticals's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RVL Pharmaceuticals's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where RVL Pharmaceuticals's 5-Year ROIIC % falls into.



RVL Pharmaceuticals 5-Year ROIIC % Calculation

RVL Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -45.661728 (Dec. 2022) - 10.0490072 (Dec. 2017) )/( 79.243 (Dec. 2022) - 818.165 (Dec. 2017) )
=-55.7107352/-738.922
=7.54%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


RVL Pharmaceuticals  (OTCPK:RVLPQ) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


RVL Pharmaceuticals 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of RVL Pharmaceuticals's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


RVL Pharmaceuticals (RVL Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
Executives
Foundation Harsaul 10 percent owner EDIFICIO AFRA, AVENIDA SAMUEL LEWIS Y CALLE 54, PANAMA R1
Altchem Ltd 10 percent owner KARAISKAKI 6, CITY HOUSE, LIMASSOL G4 3032
Alisa Lask director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
David F Burgstahler director, 10 percent owner C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Athyrium Opportunities Associates Iv Co-invest Llc 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Gp Llc 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Co-invest 2 Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Acquisition 2 Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Funds Gp Holdings Llc 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Avista Healthcare Partners, L.p. 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Brian A Markison director, officer: Chief Executive Officer 501 FIFTH STREET, BRISTOL TN 37620
Sriram Venkataraman director, 10 percent owner C/O AVISTA CAPITAL PARTNERS, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jeffrey Ferrell 10 percent owner ATHYRIUM CAPITAL MANAGEMENT, LP, 505 FIFTH AVENUE, FL 18, NEW YORK NY 10017
James Schaub officer: EVP and COO 400 CROSSING BOULEVARD, C/O OSMOTICA PHARMACEUTICALS PLC, BRIDGEWATER NJ 08807